Cpdm mice that express catalytically inactive RIP1K45A do not develop dermatitis or systemic inflammation (Berger et al., 2014), and treatment with a RIP1 inhibitor, even starting at 6 weeks of age when there is disease induction, provides significant amelioration of the dermatitis and reduces immune infiltrates in the liver (Webster et al., 2020). Here, RIPK1 is linked to dermatitis.